Data gathered: October 13
AI Stock Analysis - X4 Pharmaceuticals (XFOR)
Analysis generated October 13, 2025. Powered by Chat GPT.
X4 Pharmaceuticals is a biopharmaceutical company focused on the development of novel therapeutics for the treatment of rare diseases. Leveraging its expertise in the field, the company aims to address serious unmet medical needs through innovative research and drug development.
Stock Alerts - X4 Pharmaceuticals (XFOR)
 |
X4 Pharmaceuticals | October 10 Price is down by -7.3% in the last 24h. |
|
X4 Pharmaceuticals | October 7 Price is up by 6.8% in the last 24h. |
|
X4 Pharmaceuticals | October 2 Price is down by -7.5% in the last 24h. |
|
X4 Pharmaceuticals | October 1 Price is up by 7.9% in the last 24h. |
Download our app to get future alerts delivered in real-time.
Alternative Data for X4 Pharmaceuticals
| Alternative Data | Value | 3m Change | Trend | Benchmark |
|---|---|---|---|---|
| Job Posts | 2 | Sign up | Sign up | Sign up |
| Sentiment | 100 | Sign up | Sign up | Sign up |
| Webpage traffic | 6,000 | Sign up | Sign up | Sign up |
| Employee Rating | 94 | Sign up | Sign up | Sign up |
| Google Trends | N/A | Sign up | Sign up | Sign up |
| 4chan Mentions | N/A | Sign up | Sign up | Sign up |
| Reddit Mentions | N/A | Sign up | Sign up | Sign up |
| Stocktwits Mentions | 7 | Sign up | Sign up | Sign up |
| Stocktwits Subscribers | 3,717 | Sign up | Sign up | Sign up |
| Twitter Followers | 1,091 | Sign up | Sign up | Sign up |
| Twitter Mentions | 5 | Sign up | Sign up | Sign up |
| X Mentions | 4 | Sign up | Sign up | Sign up |
| News Mentions | N/A | Sign up | Sign up | Sign up |
| Customer reviews | N/A | Sign up | Sign up | Sign up |
| Business Outlook | 88 | Sign up | Sign up | Sign up |
| Linkedin Employees | 100 | Sign up | Sign up | Sign up |
About X4 Pharmaceuticals
X4 Pharmaceuticals, Inc., a late-stage clinical biopharmaceutical company, focuses on the research, development, and commercialization of novel therapeutics for the treatment of rare diseases.
| Price | $3.04 |
| Target Price | Sign up |
| Volume | 129,070 |
| Market Cap | $69M |
| Year Range | $1.42 - $18.51 |
| Dividend Yield | 0% |
| PE Ratio | 0.67 |
| Analyst Rating | 100% buy |
| Industry | Biotechnology |
In the news
 |
X4 Pharmaceuticals announces restructuring, 50% reduction in workforceSeptember 17 - Thefly.com |
X4 Pharmaceuticals Announces Restructuring of Business Operations Designed to Drive Long-Term Value CreationSeptember 17 - GlobeNewswire |
|
 |
X4 Pharmaceuticals, Inc. (NASDAQ:XFOR) Short Interest Down 37.2% in AugustSeptember 15 - ETF Daily News |
 |
X4 Pharmaceuticals files to sell 59.89M shares of common stock for holdersSeptember 10 - Thefly.com |
|
Charles Schwab Investment Management Inc. Raises Stake in X4 Pharmaceuticals, Inc. $XFORSeptember 5 - ETF Daily News |
 |
Stifel Nicolaus Cuts X4 Pharmaceuticals (NASDAQ:XFOR) Price Target to $9.00August 31 - ETF Daily News |
Financial performance View All
| Revenue | Cost of Revenue | Gross Profit | Net Income | ebitda | EPS | |
|---|---|---|---|---|---|---|
| Q2 '25 | 2M | 330,000 | 1.6M | -26M | 0 | -3.470 |
| Q1 '25 | 29M | 4.7M | 24M | 280,000 | 3M | 0.040 |
| Q4 '24 | 1.4M | 300,000 | 1.1M | -40M | -37M | -0.200 |
| Q3 '24 | 560,000 | 230,000 | 330,000 | -37M | -34M | -0.180 |
| Q2 '24 | 560,000 | 270,000 | 300,000 | 91M | -34M | -0.070 |
Insider Transactions View All
| Baldry Mark filed to buy 25,337 shares at $2.5. May 20 '25 |
| Arbet-Engels Christophe filed to sell 14,207 shares at $0.5. January 27 '25 |
| DiBiase Mary filed to sell 490,980 shares at $0.5. January 27 '25 |
| Baldry Mark filed to sell 94,123 shares at $0.5. January 27 '25 |
Similar companies
Read more about X4 Pharmaceuticals (XFOR) and their ai stock analysis, price prediction, earnings, congress trading, insider transactions, technical analysis, job posts, sentiment, webpage traffic, employee rating, google trends, 4chan mentions, reddit mentions, stocktwits mentions, stocktwits subscribers, twitter followers, twitter mentions, x mentions, news mentions, customer reviews, business outlook & linkedin employees.
What is the Market Cap of X4 Pharmaceuticals?
The Market Cap of X4 Pharmaceuticals is $69M.
What is X4 Pharmaceuticals' PE Ratio?
As of today, X4 Pharmaceuticals' PE (Price to Earnings) ratio is 0.67.
What is the current stock price of X4 Pharmaceuticals?
Currently, the price of one share of X4 Pharmaceuticals stock is $3.04.
How can I analyze the XFOR stock price chart for investment decisions?
The XFOR stock price chart above provides a comprehensive visual representation of X4 Pharmaceuticals' stock performance over time. Investors can use this chart to identify patterns, trends, and potential support or resistance levels. By examining historical data and recent price movements, investors can make more informed decisions regarding buying, holding, or selling X4 Pharmaceuticals shares. Our platform offers an up-to-date XFOR stock price chart, along with technical data analysis and alternative data insights.
Does XFOR offer dividends to its shareholders?
As of our latest update, X4 Pharmaceuticals (XFOR) does not offer dividends to its shareholders. Investors interested in X4 Pharmaceuticals should consider the potential for capital appreciation as the primary return on investment, rather than expecting dividend payouts.
What are some of the similar stocks of X4 Pharmaceuticals?
Some of the similar stocks of X4 Pharmaceuticals are Amgen, Gilead Sciences, Catalyst Pharmaceuticals, Inovio Pharmaceuticals, and Anavex Life Sciences.
.
